Drugs / MG-ZG122
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05659927 | Feb 2023 → Jan 2024 | asthma | Shanghai Mabgeek Biotech.Co.Ltd | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07054034 | May 2025 → May 2026 overdue | asthma | Shanghai Mabgeek Biotech.Co.Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG-ZG122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05659927 ↗ |
| Modality | Monoclonal antibody | “MG-ZG122 Humanized Monoclonal Antibody Injection” NCT07054034 ↗ |
| Route | Subcutaneous | “receive subcutaneously (SC) a single dose of MG-ZG122 or placebo” PMID 41144273 ↗ Oct 2025 |